Primer on Tumor Immunology and Biological Therapy
of Cancer

October 30, 2008
Westin Gaslamp Quarter Hotel
San Diego, CA

This Primer provided a current overview of immunology as it applies to cancer etiology, biology and therapy. The target audience for this program included basic and clinical investigators from academic, regulatory, and biopharmaceutical venues. The audience included clinicians, researchers, students, post-doctoral fellows, and allied health professionals.

Topics Addressed
  • Adoptive T Cell Therapy
  • Anti-Angiogenic Therapies
  • Antibody Therapy of Cancer
  • Approach to Identifying and Therapeutic Exploitation of Tumor Antigens
  • Blocking Anti-T Cell Checkpoints
  • Cytokines
  • Immune Adjuvants
  • Immune Monitoring
  • Mechanisms of Immune-Mediated Tumor Lysis
  • T Reg Cells

Program Goals
Attendees will learn the current status and the most recent advances in biologic therapies including cancer vaccines, vaccine adjuvants, host-tumor interactions and the role of the innate and adaptive immune systems in tumor immunology and therapy.

Expected Learner Outcomes
At the completion of this activity, participants will be able to:

  • Discuss immunology as it applies to cancer etiology, biology and therapy
  • Review key cellular immunology and the host-tumor-immune system interactions
  • Summarize humorally-based immune therapies
  • Assess cytokine biology and its role in cancer therapy
  • Evaluate the foundation and methods for clinical trials of biologic/immunologic therapies

Kim Margolin, MD
University of Washington
Patrick Hwu, MD
MD Anderson Cancer Center